Weekly Investment Analysts’ Ratings Updates for Acrivon Therapeutics (ACRV)

A number of firms have modified their ratings and price targets on shares of Acrivon Therapeutics (NASDAQ: ACRV) recently:

• 9/16/2024 – Acrivon Therapeutics had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $28.00 price target on the stock, up previously from $25.00.
• 9/16/2024 – Acrivon Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
• 9/16/2024 – Acrivon Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
• 9/16/2024 – Acrivon Therapeutics was upgraded by analysts at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating. They now have a $16.00 price target on the stock.
• 9/6/2024 – Acrivon Therapeutics had its “buy” rating reaffirmed by analysts at Piper Sandler Companies. They now have a $30.00 price target on the stock.
• 8/13/2024 – Acrivon Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.

Acrivon Therapeutics Price Performance

NASDAQ:ACRV opened at $6.98 on Wednesday. The firm has a market cap of $215.52 million, a price-to-earnings ratio of -2.42 and a beta of 0.81. The firm’s fifty day moving average price is $8.12 and its 200 day moving average price is $7.83. Acrivon Therapeutics, Inc. has a 1-year low of $3.19 and a 1-year high of $11.90.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its earnings results on Tuesday, August 13th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.08. As a group, analysts expect that Acrivon Therapeutics, Inc. will post -2.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC lifted its position in shares of Acrivon Therapeutics by 78.2% in the second quarter. Perceptive Advisors LLC now owns 5,360,858 shares of the company’s stock valued at $31,093,000 after acquiring an additional 2,353,000 shares in the last quarter. Marshall Wace LLP raised its stake in Acrivon Therapeutics by 58.8% in the 2nd quarter. Marshall Wace LLP now owns 948,866 shares of the company’s stock valued at $5,503,000 after purchasing an additional 351,397 shares during the last quarter. Sands Capital Ventures LLC lifted its holdings in Acrivon Therapeutics by 28.4% in the 2nd quarter. Sands Capital Ventures LLC now owns 2,122,605 shares of the company’s stock valued at $12,311,000 after purchasing an additional 470,000 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Acrivon Therapeutics during the 2nd quarter worth about $61,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Acrivon Therapeutics during the 2nd quarter worth about $58,000. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.